The 12 mg arm started at 2 mg and increased every four weeks through 4 mg, 6 mg, 9 mg, and 12 mg
The GLOW stack combining all three uses these typical ratios
The reduction in IL-4, IL-5, and IL-13 coincided with enhanced IL-12 expression, indicating regulation of the Th1/Th2 balance [61]
Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key: A Special Beneficial Pleiotropic Effect Controlling and Modulating Angiogenesis and the NO-System, Sikiric P, Seiwerth S, Skrtic A, Staresinic M, Strbe S, Vuksic A, Sikiric S, Bekic D, Soldo D, Grizelj B, Novosel L, Beketic Oreskovic L, Oreskovic I, Stupnisek M, Boban Blagaic A, Dobric I, Pharmaceuticals (Basel), Pharmaceuticals, 2025 Jun 19;18(6):928
Some research community protocols combine 5-Amino-1MQ with AOD-9604 (fat oxidation) or with a GLP-1 drug like semaglutide (appetite suppression), since the mechanisms do not overlap